BCRX Stock Overview
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BioCryst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.67 |
| 52 Week High | US$9.07 |
| 52 Week Low | US$4.45 |
| Beta | 1.93 |
| 1 Month Change | -6.60% |
| 3 Month Change | -23.32% |
| 1 Year Change | -42.13% |
| 3 Year Change | -59.43% |
| 5 Year Change | -42.70% |
| Change since IPO | -28.15% |
Recent News & Updates
Recent updates
BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24BioCryst: BCX9930's Hiccup Affects The Entire Company
Apr 11BioCryst Pharmaceuticals: Updates To Thesis, Clinical And Commercial Momentum Accelerating
Feb 03Shareholder Returns
| BCRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | -2.8% | -1.7% |
| 1Y | -42.1% | -0.2% | 22.4% |
Return vs Industry: BCRX underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: BCRX underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| BCRX volatility | |
|---|---|
| BCRX Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCRX's share price has been volatile over the past 3 months.
Volatility Over Time: BCRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 536 | Jon Stonehouse | www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases.
BioCryst Pharmaceuticals, Inc. Fundamentals Summary
| BCRX fundamental statistics | |
|---|---|
| Market cap | US$983.34m |
| Earnings (TTM) | -US$226.54m |
| Revenue (TTM) | US$331.41m |
2.9x
P/S Ratio-4.2x
P/E RatioIs BCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCRX income statement (TTM) | |
|---|---|
| Revenue | US$331.41m |
| Cost of Revenue | US$216.65m |
| Gross Profit | US$114.76m |
| Other Expenses | US$341.30m |
| Earnings | -US$226.54m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 34.63% |
| Net Profit Margin | -68.36% |
| Debt/Equity Ratio | -183.3% |
How did BCRX perform over the long term?
See historical performance and comparison